Standardized Definitions of In Utero Human Immunodeficiency Virus and Antiretroviral Drug Exposure Among Children
Abstract In countries with high human immunodeficiency virus (HIV) prevalence, up to 30% of pregnant women are living with HIV, with fetal exposure to both HIV and antiretroviral therapy during pregnancy. In addition, pregnant women without HIV but at high risk of HIV acquisition are increasingly re...
Gespeichert in:
Veröffentlicht in: | Clinical infectious diseases 2022-08, Vol.75 (2), p.347-355 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 355 |
---|---|
container_issue | 2 |
container_start_page | 347 |
container_title | Clinical infectious diseases |
container_volume | 75 |
creator | Slogrove, Amy L Burmen, Barbara Davies, Mary Ann Edmonds, Andrew Abrams, Elaine J Chadwick, Ellen G Goetghebuer, Tessa Mofenson, Lynne M Paul, Mary E Thorne, Claire Williams, Paige L Vicari, Marissa Powis, Kathleen M |
description | Abstract
In countries with high human immunodeficiency virus (HIV) prevalence, up to 30% of pregnant women are living with HIV, with fetal exposure to both HIV and antiretroviral therapy during pregnancy. In addition, pregnant women without HIV but at high risk of HIV acquisition are increasingly receiving HIV preexposure antiretroviral prophylaxis (PrEP). Investments are being made to establish and follow cohorts of children to evaluate the long-term effects of in utero HIV and antiretroviral exposure. Agreement on a key set of definitions for relevant exposures and outcomes is important both for interpreting individual study results and for comparisons across cohorts. Harmonized definitions of in utero HIV and antiretroviral drug (maternal treatment or PrEP) exposure will also facilitate improved classification of these exposures in future observational studies and clinical trials. The proposed definitions offer a uniform approach to facilitate the consistent description and estimation of effects of HIV and antiretroviral exposures on key child health outcomes.
In countries with high human immunodeficiency virus (HIV) prevalence, 20%–30% of pregnant women have HIV and receive antiretrovirals. Proposed definitions offer a uniform approach to describing/estimating the effects of in utero HIV and antiretroviral exposure on child health outcomes. |
doi_str_mv | 10.1093/cid/ciab974 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9410726</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/cid/ciab974</oup_id><sourcerecordid>2630926273</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-73b1d0bfe59d9a74577013acbe5eec09d2f91c91d2c2e2c08989c4c0468abf1a3</originalsourceid><addsrcrecordid>eNp9kc1rGzEQxUVoiNMkp96LTqUQNpX2w5IuBWOnjSGQQ5NchVaatVV2JUdahTp_fRTshuSSwzAD85s3Dx5CXyi5oERUP7Q1uVQrWH2AjmlTsWLaCPopz6ThRc0rPkGfY_xLCKWcNEdoUjWUU8bFMXr4MypnVDD2CQxeQGedHa13EfsOLx2-GyF4fJUG5fByGJLzJjPagtNbfG9Dijjf45kbbYAx-EcbVI8XIa3w5b-NjykAng3erfB8bXsTwJ2iw071Ec72_QTd_bq8nV8V1ze_l_PZdaFrWo4Fq1pqSNtBI4xQrG4YI7RSuoUGQBNhyk5QLagpdQmlJlxwoWtN6ilXbUdVdYJ-7nQ3qR3AaHBjtiY3wQ4qbKVXVr7fOLuWK_8oRU0JK6dZ4PteIPiHBHGUg40a-l458CnKjBBRTktWZfR8h-rgYwzQvb6hRL6EJHNIch9Spr--dfbK_k8lA992gE-bD5WeAX-5ntM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2630926273</pqid></control><display><type>article</type><title>Standardized Definitions of In Utero Human Immunodeficiency Virus and Antiretroviral Drug Exposure Among Children</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Slogrove, Amy L ; Burmen, Barbara ; Davies, Mary Ann ; Edmonds, Andrew ; Abrams, Elaine J ; Chadwick, Ellen G ; Goetghebuer, Tessa ; Mofenson, Lynne M ; Paul, Mary E ; Thorne, Claire ; Williams, Paige L ; Vicari, Marissa ; Powis, Kathleen M</creator><creatorcontrib>Slogrove, Amy L ; Burmen, Barbara ; Davies, Mary Ann ; Edmonds, Andrew ; Abrams, Elaine J ; Chadwick, Ellen G ; Goetghebuer, Tessa ; Mofenson, Lynne M ; Paul, Mary E ; Thorne, Claire ; Williams, Paige L ; Vicari, Marissa ; Powis, Kathleen M</creatorcontrib><description>Abstract
In countries with high human immunodeficiency virus (HIV) prevalence, up to 30% of pregnant women are living with HIV, with fetal exposure to both HIV and antiretroviral therapy during pregnancy. In addition, pregnant women without HIV but at high risk of HIV acquisition are increasingly receiving HIV preexposure antiretroviral prophylaxis (PrEP). Investments are being made to establish and follow cohorts of children to evaluate the long-term effects of in utero HIV and antiretroviral exposure. Agreement on a key set of definitions for relevant exposures and outcomes is important both for interpreting individual study results and for comparisons across cohorts. Harmonized definitions of in utero HIV and antiretroviral drug (maternal treatment or PrEP) exposure will also facilitate improved classification of these exposures in future observational studies and clinical trials. The proposed definitions offer a uniform approach to facilitate the consistent description and estimation of effects of HIV and antiretroviral exposures on key child health outcomes.
In countries with high human immunodeficiency virus (HIV) prevalence, 20%–30% of pregnant women have HIV and receive antiretrovirals. Proposed definitions offer a uniform approach to describing/estimating the effects of in utero HIV and antiretroviral exposure on child health outcomes.</description><identifier>ISSN: 1058-4838</identifier><identifier>ISSN: 1537-6591</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/ciab974</identifier><identifier>PMID: 35181789</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Anti-HIV Agents - adverse effects ; Anti-Retroviral Agents - therapeutic use ; Child ; Female ; HIV ; HIV Infections - prevention & control ; Humans ; Infectious Disease Transmission, Vertical - prevention & control ; Pre-Exposure Prophylaxis ; Pregnancy ; Pregnancy Complications, Infectious - drug therapy ; Viewpoints</subject><ispartof>Clinical infectious diseases, 2022-08, Vol.75 (2), p.347-355</ispartof><rights>The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. 2021</rights><rights>The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-73b1d0bfe59d9a74577013acbe5eec09d2f91c91d2c2e2c08989c4c0468abf1a3</citedby><cites>FETCH-LOGICAL-c412t-73b1d0bfe59d9a74577013acbe5eec09d2f91c91d2c2e2c08989c4c0468abf1a3</cites><orcidid>0000-0002-8046-9268</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,1578,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35181789$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Slogrove, Amy L</creatorcontrib><creatorcontrib>Burmen, Barbara</creatorcontrib><creatorcontrib>Davies, Mary Ann</creatorcontrib><creatorcontrib>Edmonds, Andrew</creatorcontrib><creatorcontrib>Abrams, Elaine J</creatorcontrib><creatorcontrib>Chadwick, Ellen G</creatorcontrib><creatorcontrib>Goetghebuer, Tessa</creatorcontrib><creatorcontrib>Mofenson, Lynne M</creatorcontrib><creatorcontrib>Paul, Mary E</creatorcontrib><creatorcontrib>Thorne, Claire</creatorcontrib><creatorcontrib>Williams, Paige L</creatorcontrib><creatorcontrib>Vicari, Marissa</creatorcontrib><creatorcontrib>Powis, Kathleen M</creatorcontrib><title>Standardized Definitions of In Utero Human Immunodeficiency Virus and Antiretroviral Drug Exposure Among Children</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Abstract
In countries with high human immunodeficiency virus (HIV) prevalence, up to 30% of pregnant women are living with HIV, with fetal exposure to both HIV and antiretroviral therapy during pregnancy. In addition, pregnant women without HIV but at high risk of HIV acquisition are increasingly receiving HIV preexposure antiretroviral prophylaxis (PrEP). Investments are being made to establish and follow cohorts of children to evaluate the long-term effects of in utero HIV and antiretroviral exposure. Agreement on a key set of definitions for relevant exposures and outcomes is important both for interpreting individual study results and for comparisons across cohorts. Harmonized definitions of in utero HIV and antiretroviral drug (maternal treatment or PrEP) exposure will also facilitate improved classification of these exposures in future observational studies and clinical trials. The proposed definitions offer a uniform approach to facilitate the consistent description and estimation of effects of HIV and antiretroviral exposures on key child health outcomes.
In countries with high human immunodeficiency virus (HIV) prevalence, 20%–30% of pregnant women have HIV and receive antiretrovirals. Proposed definitions offer a uniform approach to describing/estimating the effects of in utero HIV and antiretroviral exposure on child health outcomes.</description><subject>Anti-HIV Agents - adverse effects</subject><subject>Anti-Retroviral Agents - therapeutic use</subject><subject>Child</subject><subject>Female</subject><subject>HIV</subject><subject>HIV Infections - prevention & control</subject><subject>Humans</subject><subject>Infectious Disease Transmission, Vertical - prevention & control</subject><subject>Pre-Exposure Prophylaxis</subject><subject>Pregnancy</subject><subject>Pregnancy Complications, Infectious - drug therapy</subject><subject>Viewpoints</subject><issn>1058-4838</issn><issn>1537-6591</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1rGzEQxUVoiNMkp96LTqUQNpX2w5IuBWOnjSGQQ5NchVaatVV2JUdahTp_fRTshuSSwzAD85s3Dx5CXyi5oERUP7Q1uVQrWH2AjmlTsWLaCPopz6ThRc0rPkGfY_xLCKWcNEdoUjWUU8bFMXr4MypnVDD2CQxeQGedHa13EfsOLx2-GyF4fJUG5fByGJLzJjPagtNbfG9Dijjf45kbbYAx-EcbVI8XIa3w5b-NjykAng3erfB8bXsTwJ2iw071Ec72_QTd_bq8nV8V1ze_l_PZdaFrWo4Fq1pqSNtBI4xQrG4YI7RSuoUGQBNhyk5QLagpdQmlJlxwoWtN6ilXbUdVdYJ-7nQ3qR3AaHBjtiY3wQ4qbKVXVr7fOLuWK_8oRU0JK6dZ4PteIPiHBHGUg40a-l458CnKjBBRTktWZfR8h-rgYwzQvb6hRL6EJHNIch9Spr--dfbK_k8lA992gE-bD5WeAX-5ntM</recordid><startdate>20220825</startdate><enddate>20220825</enddate><creator>Slogrove, Amy L</creator><creator>Burmen, Barbara</creator><creator>Davies, Mary Ann</creator><creator>Edmonds, Andrew</creator><creator>Abrams, Elaine J</creator><creator>Chadwick, Ellen G</creator><creator>Goetghebuer, Tessa</creator><creator>Mofenson, Lynne M</creator><creator>Paul, Mary E</creator><creator>Thorne, Claire</creator><creator>Williams, Paige L</creator><creator>Vicari, Marissa</creator><creator>Powis, Kathleen M</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8046-9268</orcidid></search><sort><creationdate>20220825</creationdate><title>Standardized Definitions of In Utero Human Immunodeficiency Virus and Antiretroviral Drug Exposure Among Children</title><author>Slogrove, Amy L ; Burmen, Barbara ; Davies, Mary Ann ; Edmonds, Andrew ; Abrams, Elaine J ; Chadwick, Ellen G ; Goetghebuer, Tessa ; Mofenson, Lynne M ; Paul, Mary E ; Thorne, Claire ; Williams, Paige L ; Vicari, Marissa ; Powis, Kathleen M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-73b1d0bfe59d9a74577013acbe5eec09d2f91c91d2c2e2c08989c4c0468abf1a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Anti-HIV Agents - adverse effects</topic><topic>Anti-Retroviral Agents - therapeutic use</topic><topic>Child</topic><topic>Female</topic><topic>HIV</topic><topic>HIV Infections - prevention & control</topic><topic>Humans</topic><topic>Infectious Disease Transmission, Vertical - prevention & control</topic><topic>Pre-Exposure Prophylaxis</topic><topic>Pregnancy</topic><topic>Pregnancy Complications, Infectious - drug therapy</topic><topic>Viewpoints</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Slogrove, Amy L</creatorcontrib><creatorcontrib>Burmen, Barbara</creatorcontrib><creatorcontrib>Davies, Mary Ann</creatorcontrib><creatorcontrib>Edmonds, Andrew</creatorcontrib><creatorcontrib>Abrams, Elaine J</creatorcontrib><creatorcontrib>Chadwick, Ellen G</creatorcontrib><creatorcontrib>Goetghebuer, Tessa</creatorcontrib><creatorcontrib>Mofenson, Lynne M</creatorcontrib><creatorcontrib>Paul, Mary E</creatorcontrib><creatorcontrib>Thorne, Claire</creatorcontrib><creatorcontrib>Williams, Paige L</creatorcontrib><creatorcontrib>Vicari, Marissa</creatorcontrib><creatorcontrib>Powis, Kathleen M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Slogrove, Amy L</au><au>Burmen, Barbara</au><au>Davies, Mary Ann</au><au>Edmonds, Andrew</au><au>Abrams, Elaine J</au><au>Chadwick, Ellen G</au><au>Goetghebuer, Tessa</au><au>Mofenson, Lynne M</au><au>Paul, Mary E</au><au>Thorne, Claire</au><au>Williams, Paige L</au><au>Vicari, Marissa</au><au>Powis, Kathleen M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Standardized Definitions of In Utero Human Immunodeficiency Virus and Antiretroviral Drug Exposure Among Children</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2022-08-25</date><risdate>2022</risdate><volume>75</volume><issue>2</issue><spage>347</spage><epage>355</epage><pages>347-355</pages><issn>1058-4838</issn><issn>1537-6591</issn><eissn>1537-6591</eissn><abstract>Abstract
In countries with high human immunodeficiency virus (HIV) prevalence, up to 30% of pregnant women are living with HIV, with fetal exposure to both HIV and antiretroviral therapy during pregnancy. In addition, pregnant women without HIV but at high risk of HIV acquisition are increasingly receiving HIV preexposure antiretroviral prophylaxis (PrEP). Investments are being made to establish and follow cohorts of children to evaluate the long-term effects of in utero HIV and antiretroviral exposure. Agreement on a key set of definitions for relevant exposures and outcomes is important both for interpreting individual study results and for comparisons across cohorts. Harmonized definitions of in utero HIV and antiretroviral drug (maternal treatment or PrEP) exposure will also facilitate improved classification of these exposures in future observational studies and clinical trials. The proposed definitions offer a uniform approach to facilitate the consistent description and estimation of effects of HIV and antiretroviral exposures on key child health outcomes.
In countries with high human immunodeficiency virus (HIV) prevalence, 20%–30% of pregnant women have HIV and receive antiretrovirals. Proposed definitions offer a uniform approach to describing/estimating the effects of in utero HIV and antiretroviral exposure on child health outcomes.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>35181789</pmid><doi>10.1093/cid/ciab974</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-8046-9268</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1058-4838 |
ispartof | Clinical infectious diseases, 2022-08, Vol.75 (2), p.347-355 |
issn | 1058-4838 1537-6591 1537-6591 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9410726 |
source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | Anti-HIV Agents - adverse effects Anti-Retroviral Agents - therapeutic use Child Female HIV HIV Infections - prevention & control Humans Infectious Disease Transmission, Vertical - prevention & control Pre-Exposure Prophylaxis Pregnancy Pregnancy Complications, Infectious - drug therapy Viewpoints |
title | Standardized Definitions of In Utero Human Immunodeficiency Virus and Antiretroviral Drug Exposure Among Children |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T00%3A28%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Standardized%20Definitions%20of%20In%20Utero%20Human%20Immunodeficiency%20Virus%20and%20Antiretroviral%20Drug%20Exposure%20Among%20Children&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Slogrove,%20Amy%20L&rft.date=2022-08-25&rft.volume=75&rft.issue=2&rft.spage=347&rft.epage=355&rft.pages=347-355&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/ciab974&rft_dat=%3Cproquest_pubme%3E2630926273%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2630926273&rft_id=info:pmid/35181789&rft_oup_id=10.1093/cid/ciab974&rfr_iscdi=true |